Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Intensive chemo is used before treatment with gene-editing medicines, including Vertex's CRISPR Therapeutics-partnered Casgevy (exagamglogene autotemcel), which became the first based on the ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

The Medicines and Healthcare products Regulatory Agency (MHRA) cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...